Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

被引：0
|
作者：
Hida, Toyoaki [1 ]
机构：
[1] Cent Japan Int Med Ctr, Lung Canc Ctr, Minokamo, Gifu 5058510, Japan
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2024年 / 13卷 / 04期
关键词：
Antibody-drug conjugates (ADCs); EGFR-tyrosine kinase inhibitor resistance (EGFR-TKI resistance); MET gene alterations; biparatopic antibodies (biparatopic Abs); bystander effect; PHASE; 1/2; EFFICACY; REGN5093-M114; TOLERABILITY; COMBINATION;
D O I：
10.21037/tlcr-24-100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：936 / 939
页数：4
相关论文
共 50 条
  • [1] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [2] MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
    Felip, E.
    Minotti, V.
    Soo, R.
    Wolf, J.
    Solomon, B.
    Tan, D. S. W.
    Ardizzoni, A.
    Lee, D. H.
    Sequist, L. V.
    Barlesi, F.
    Paz-Ares, L.
    Rodriguez-Abreu, D.
    Garcia Campelo, M. R.
    Sprauten, M.
    Djentuh, L. O'Sullivan
    Belli, R.
    Glaser, S.
    Zou, M.
    Giovannini, M.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2020, 31 : S829 - S830
  • [3] Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non-Small-Cell Lung Cancer
    Hendriks, Lizza E. L.
    Remon, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (35) : 5351 - 2023
  • [4] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [5] Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Kim, Soomin
    Koh, Jaemoon
    Kim, Tae Min
    Oh, Songji
    Kim, Soyeon
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Heo, Dae Seog
    ISCIENCE, 2025, 28 (02)
  • [6] Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer
    Lim, Sun Min
    Kim, Chang Gon
    Cho, Byoung Chul
    CANCER RESEARCH, 2022, 82 (01) : 18 - 20
  • [7] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
    Jassem, Jacek
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
  • [8] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [9] Editorial Comment on Validation of the digital PCR system for use in tyrosine kinase inhibitor-resistant EGFR-mutant non-small-cell lung cancer
    Sugimura, Haruhiko
    Kahyo, Tomoaki
    PATHOLOGY INTERNATIONAL, 2018, 68 (03) : 174 - 175
  • [10] Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Salvatore Corallo
    Ettore D’Argento
    Antonia Strippoli
    Michele Basso
    Santa Monterisi
    Sabrina Rossi
    Alessandra Cassano
    Carlo M. Barone
    Targeted Oncology, 2017, 12 : 153 - 161
12345